deucravacitinib 3 mg tablet
Sponsors
Bristol Myers Squibb International Corporation, Bristol-Myers Squibb Services Unlimited Company
Conditions
Active Discoid and/or Subacute Cutaneous Lupus Erythematosus
(DLE/SCLE)Systemic Lupus Erythematosus
Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants with Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Active, not recruitingCTIS2023-504161-22-00
Start: 2021-06-04Target: 36Updated: 2025-12-22
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus
CompletedCTIS2022-502444-13-00
Start: 2019-05-28End: 2025-03-10Target: 63Updated: 2024-12-23